Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2010. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding their interests in the company's Ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure of share transactions and does not contain financial performance data.
Material Changes
The filing details the acquisition of Ordinary shares by nine individuals on October 7, 2010, at a price of £12.94 per share. These acquisitions were executed through the Dividend Reinvestment element of the Company's Share Reward Plan, which the individuals entered on October 5, 2001. The specific share counts acquired were:
- Mr A P Witty: 28 shares
- Mr J S Heslop: 28 shares
- Mr S M Bicknell: 28 shares
- Mr E J Gray: 28 shares
- Mr S A Hussain: 6 shares
- Dr D Pulman: 10 shares
- Mr D S Redfern: 28 shares
- Ms C Thomas: 28 shares
- Mr P J T Vallance: 11 shares
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of the aforementioned share transactions in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Share price for the transaction was £12.94 per Ordinary share.
- Transactions occurred on October 7, 2010, and were notified on October 8, 2010.
- All listed acquisitions were made via the Dividend Reinvestment element of the Share Reward Plan.
- The filing does not contain financial results or strategic updates.